Abstract
More than 50 years after spironolactone has come on the market its mechanism of action continues to expand. In this issue of Circulation Research, Good et al. document the discovery that spironolactone is not only an inhibitor of the mineralocorticoid receptor, but also inhibits pannexin 1 channels.